Division of Cancer Therapeutics
Suzanne A. Eccles has not added Biography.
If you are Suzanne A. Eccles and would like to personalize this page please email our Author Liaison for assistance.
Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention.
The International journal of developmental biology , 2004 | Pubmed ID: 15349833
The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma.
Oral oncology Oct, 2002 | Pubmed ID: 12167415
Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients.
International journal of cancer. Journal international du cancer Nov, 2003 | Pubmed ID: 14520690
Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis.
Tumori Jan-Feb, 2004 | Pubmed ID: 15143962
Signaling pathways required for matrix metalloproteinase-9 induction by betacellulin in head-and-neck squamous carcinoma cells.
International journal of cancer. Journal international du cancer Aug, 2004 | Pubmed ID: 15197768
Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC.
Expert review of anticancer therapy Aug, 2004 | Pubmed ID: 15270661
Targeting key steps in metastatic tumour progression.
Current opinion in genetics & development Feb, 2005 | Pubmed ID: 15661537
Breast cancer metastasis: when, where, how?
Lancet Mar 19-25, 2005 | Pubmed ID: 15781080
Biological significance of c-erbB family oncogenes in head and neck cancer.
Cancer metastasis reviews Jan, 2005 | Pubmed ID: 15785872
PLCgamma1 is essential for early events in integrin signalling required for cell motility.
Journal of cell science Jun, 2005 | Pubmed ID: 15944397
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.
Expert opinion on therapeutic targets Aug, 2005 | Pubmed ID: 16083342
Cell migration/invasion assays and their application in cancer drug discovery.
Biotechnology annual review , 2005 | Pubmed ID: 16216785
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells.
Molecular cancer therapeutics Jan, 2006 | Pubmed ID: 16432178
Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
Molecular cancer therapeutics Mar, 2006 | Pubmed ID: 16546966
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Clinical cancer research : an official journal of the American Association for Cancer Research Mar, 2006 | Pubmed ID: 16551869
The phosphoinositide-specific phospholipase C inhibitor U73122 (1-(6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione) spontaneously forms conjugates with common components of cell culture medium.
Drug metabolism and disposition: the biological fate of chemicals Jul, 2007 | Pubmed ID: 17403917
Metastasis: recent discoveries and novel treatment strategies.
Lancet May, 2007 | Pubmed ID: 17512859
Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts.
Assay and drug development technologies Jun, 2007 | Pubmed ID: 17638539
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
Journal of medicinal chemistry Jan, 2008 | Pubmed ID: 18020435
Plexin-B1 mutations in prostate cancer.
Proceedings of the National Academy of Sciences of the United States of America Nov, 2007 | Pubmed ID: 18024597
AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 4.
IDrugs : the investigational drugs journal Dec, 2007 | Pubmed ID: 18041676
The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research Dec, 2007 | Pubmed ID: 18056200
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
Cancer chemotherapy and pharmacology Oct, 2008 | Pubmed ID: 18193424
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
Cancer research Apr, 2008 | Pubmed ID: 18413753
CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.
Cancer research Aug, 2008 | Pubmed ID: 18701491
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
Journal of medicinal chemistry Sep, 2008 | Pubmed ID: 18754654
A microRNA DNA methylation signature for human cancer metastasis.
Proceedings of the National Academy of Sciences of the United States of America Sep, 2008 | Pubmed ID: 18768788
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma.
Cell cycle (Georgetown, Tex.) Feb, 2009 | Pubmed ID: 19177002
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
The Journal of pathology May, 2009 | Pubmed ID: 19197951
In vitro assays for endothelial cell functions related to angiogenesis: proliferation, motility, tubular differentiation, and proteolysis.
Methods in molecular biology (Clifton, N.J.) , 2009 | Pubmed ID: 19301670
The identification of novel PLC-gamma inhibitors using virtual high throughput screening.
Bioorganic & medicinal chemistry Apr, 2009 | Pubmed ID: 19303309
Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells.
Molecular cancer therapeutics May, 2009 | Pubmed ID: 19417158
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Molecular cancer therapeutics Jul, 2009 | Pubmed ID: 19584227
Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.
Journal of medicinal chemistry Aug, 2009 | Pubmed ID: 19610616
Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage.
The American journal of pathology Sep, 2009 | Pubmed ID: 19661439
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Molecular cancer therapeutics Jan, 2010 | Pubmed ID: 20053762
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).
Journal of medicinal chemistry Mar, 2010 | Pubmed ID: 20151677
Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.
Molecular cancer therapeutics May, 2010 | Pubmed ID: 20457619
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.
Journal of medicinal chemistry Jul, 2010 | Pubmed ID: 20565112
Tumour-microenvironmental interactions: paths to progression and targets for treatment.
Seminars in cancer biology Jun, 2010 | Pubmed ID: 20599506
Bayesian estimation of changes in transverse relaxation rates.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine Sep, 2010 | Pubmed ID: 20806382
Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: Part 1.
IDrugs : the investigational drugs journal Nov, 2010 | Pubmed ID: 21046522
Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2.
IDrugs : the investigational drugs journal Nov, 2010 | Pubmed ID: 21046523
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
Molecular cancer therapeutics Feb, 2011 | Pubmed ID: 21191045
Angiogenic functions of voltage-gated Na+ Channels in human endothelial cells: modulation of vascular endothelial growth factor (VEGF) signaling.
The Journal of biological chemistry May, 2011 | Pubmed ID: 21385874
Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts.
International journal of cancer. Journal international du cancer Mar, 2012 | Pubmed ID: 21469141
Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
Molecular cancer therapeutics Aug, 2011 | Pubmed ID: 21659463
Simple experimental and spontaneous metastasis assays in mice.
Methods in molecular biology (Clifton, N.J.) , 2011 | Pubmed ID: 21748685
Ca2+ influx through reverse mode Na+/Ca2+ exchange is critical for vascular endothelial growth factor-mediated extracellular signal-regulated kinase (ERK) 1/2 activation and angiogenic functions of human endothelial cells.
The Journal of biological chemistry Nov, 2011 | Pubmed ID: 21873429
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Molecular cancer therapeutics Nov, 2011 | Pubmed ID: 21885865
Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
Molecular & cellular proteomics : MCP Dec, 2011 | Pubmed ID: 21955398
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.
Journal of medicinal chemistry Dec, 2011 | Pubmed ID: 22111927
The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology.
The International journal of developmental biology , 2011 | Pubmed ID: 22161825
Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.
Molecular medicine (Cambridge, Mass.) , 2012 | Pubmed ID: 22354215
Epigenetic disruption of cadherin-11 in human cancer metastasis.
The Journal of pathology Feb, 2012 | Pubmed ID: 22374749
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.
BMC biology , 2012 | Pubmed ID: 22439642
The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.
PloS one , 2012 | Pubmed ID: 22523597
Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.
Journal of clinical immunology Oct, 2012 | Pubmed ID: 22526592
Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.
Proceedings of the National Academy of Sciences of the United States of America May, 2012 | Pubmed ID: 22529373
Preclinical drug development for childhood cancer.
Expert opinion on drug discovery Jan, 2011 | Pubmed ID: 22646826
Kurt Hellmann D.M., D.Phil. Oxon. A happy 90th birthday!
Clinical & experimental metastasis Aug, 2012 | Pubmed ID: 22695808
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2012 | Pubmed ID: 22781553
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Cancer cell Jul, 2012 | Pubmed ID: 22789543
Erratum to: Kurt Hellmann D.M., D.Phil. Oxon. A happy 90th birthday!
Clinical & experimental metastasis Aug, 2012 | Pubmed ID: 22872374
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research Oct, 2012 | Pubmed ID: 22929806
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.
Journal of medicinal chemistry Oct, 2012 | Pubmed ID: 23043539
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
Journal of medicinal chemistry Nov, 2012 | Pubmed ID: 23082860
Two-dimensional vs. three-dimensional in vitro tumor migration and invasion assays.
Methods in molecular biology (Clifton, N.J.) , 2013 | Pubmed ID: 23436416
Tumor spheroid-based migration assays for evaluation of therapeutic agents.
Methods in molecular biology (Clifton, N.J.) , 2013 | Pubmed ID: 23436417
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
European journal of cancer (Oxford, England : 1990) Jul, 2013 | Pubmed ID: 23582742
A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells.
Journal of the American Chemical Society Jul, 2013 | Pubmed ID: 23796364
Kurt Hellmann D. M., D. Phil. Oxon 1922–2013.
Clinical & experimental metastasis Jun, 2013 | Pubmed ID: 23844428
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research Nov, 2013 | Pubmed ID: 23918606
Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX.
Oncotarget Nov, 2013 | Pubmed ID: 24185264
Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).
Journal of medicinal chemistry Dec, 2013 | Pubmed ID: 24256217
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.
Breast cancer research : BCR , 2013 | Pubmed ID: 24286369
Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.
Journal of the National Cancer Institute Apr, 2014 | Pubmed ID: 24634505
HIF-1α-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion.
Cancer biology & therapy Oct, 2014 | Pubmed ID: 25019382
An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2009 | Pubmed ID: 25278743
Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells.
BMC cancer , 2014 | Pubmed ID: 25512109
Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography.
Cancer research Apr, 2015 | Pubmed ID: 25672978
Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
Journal of medicinal chemistry Feb, 2015 | Pubmed ID: 25680029
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。